The UK has complex health systems with a large private sector operating alongside comprehensive public provision, and significant issues around staff shortages and an ageing population. Increasing need and rising costs can force providers and entrepreneurs to consider innovative solutions such as e-health; but technology may enable the shift from acute services toward prevention.
Contract research organisations (CROs) can use deal-making to add innovative services, or build a presence in new therapeutic areas, rare diseases, or new geographic territories.
Commercial services in pharma, healthcare, and life sciences include a fast-growing marketing sector using sophisticated tools to communicate complex information and messages to professionals and patients.
The COVID-19 pandemic proved the ability of pharmaceuticals companies to operate at scale and with agility, under intense public scrutiny.